High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: Case report

Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations

(2010) M. E. Steed et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Update on Cardiovascular Implantable Electronic Device Infections and Their Management

(2010) Larry M. Baddour et al.   CIRCULATION

Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy

(2009) Pamela A Moise et al.   ANNALS OF PHARMACOTHERAPY

Safety of High‐Dose Intravenous Daptomycin Treatment: Three‐Year Cumulative Experience in a Clinical Program

(2009) D. A. Figueroa et al.   CLINICAL INFECTIOUS DISEASES

Daptomycin: mechanisms of action and resistance, and biosynthetic engineering

(2009) Richard H Baltz   CURRENT OPINION IN CHEMICAL BIOLOGY

Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies

(2009) Matthew E Falagas et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

(2009) Nikos Roussos et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal Infections

(2008) Matthew E. Falagas et al.   CLINICAL INFECTIOUS DISEASES